HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OGN
Organon & Co.
OGN's fundamentals are mixed: it turned 11% of its revenue into free cash flow, but its operating margin fell 3 points to 8.2%. Its PE of 18x looks cheaper than it really is, because one-off gains boosted its recent earnings. Analysts expect earnings to hold roughly steady.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Weak |
OGN's revenue, profitability and cash flow are currently stable, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OGN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.7x | $2.88 | -79% |
| Forward | 4x | $13.90 | — |
| Fair | 5.6x | $4.34 | -69% |
| Expensive | 7.6x | $5.86 | -58% |
| Current | 18x | $13.90 | — |
Historical ranges are pointers, not guarantees.
OGN's PE is in its expensive range at 18x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 4.0x, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OGN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect OGN's profitability to improve, with its earnings and revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
OGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.49 | +353% |
| Q3 2026 | $0.77 | -60% |
| Q2 2026 | $0.78 | -71% |
| Q1 2026 | $0.94 | -67% |
| Q4 2025 | $0.72 | -78% |
| Q3 2025 | $1.92 | -62% |
| Q2 2025 | $2.69 | -31% |
| Q1 2025 | $2.88 | -29% |
| Q4 2024 | $3.33 | -17% |
OGN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over OGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
OGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | -1.7% |
| Q2 2026 | $1.6B | -2.3% |
| Q1 2026 | $1.5B | -3.5% |
| Q4 2025 | $1.5B | -5.3% |
| Q3 2025 | $1.6B | +1.3% |
| Q2 2025 | $1.6B | -0.8% |
| Q1 2025 | $1.5B | -6.7% |
| Q4 2024 | $1.6B | -0.4% |
OGN's revenue has held roughly level: $1.6B last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | +1 points |
| Q2 2026 | 12% | -2.6 points |
| Q1 2026 | 15% | +7.9 points |
| Q4 2025 | -9.8% | -18 points |
| Q3 2025 | 15% | +2.1 points |
| Q2 2025 | 14% | -0.3 points |
| Q1 2025 | 6.7% | -7.9 points |
| Q4 2024 | 8.1% | +1.6 points |
OGN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over OGN on cash flow, with more consistent year-over-year improvement.
OGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $326M | +50% |
| Q2 2026 | $65M | -64% |
| Q1 2026 | $188M | +337% |
| Q4 2025 | $96M | -71% |
| Q3 2025 | $218M | +120% |
| Q2 2025 | $181M | -40% |
| Q1 2025 | $43M | +43% |
| Q4 2024 | $335M | +5.3% |
OGN still generates free cash flow, though less than at its 2021 peak: $675M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over OGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
OGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +1.9M shares |
| 1 year | +4.5% | +11.7M shares |
| 3 years | +6.3% | +16M shares |
| 5 years | +7.2% | +18.2M shares |
| Available history | +7.6% | +19.3M shares |
OGN has 272M diluted shares, up 4.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
OGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 10.8x | High |
| Q2 2026 | 11.4x | High |
| Q1 2026 | 10.7x | High |
| Q4 2025 | 13.9x | High |
| Q3 2025 | 9.6x | High |
| Q2 2025 | 10.3x | High |
| Q1 2025 | 10.4x | High |
| Q4 2024 | 8.7x | High |
OGN's net debt is about 11 years of its operating earnings (EBITDA), up from 9.6 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.9 | Overbought |
| Stochastic | 99.0 | Overbought |
OGN's weekly RSI is 72 (overbought) and its Stochastic is 99 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
OGN PE vs Healthcare Sector
| Metric | OGN | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 30% below |
| PE % | 100 | 37 | 63 pts above |
OGN is trading at 18x earnings, a 30% discount to the Healthcare sector's median of 26x, though its recent earnings include one-off gains.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
OGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.8 | 0.7% above |
| 20 week MA | $13.7 | 1.5% above |
| 50 week MA | $11.1 | 25% above |
| 100 week MA | $11.2 | 24% above |
| 200 week MA | $15.4 | 9.4% below |
OGN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
OGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $33.3 | $30.2 | -9.1% |
| 2022 | $30.2 | $27.9 | -7.6% |
| 2023 | $27.9 | $14.4 | -48% |
| 2024 | $14.4 | $15.1 | +4.4% |
| 2025 | $15.1 | $7.18 | -52% |
| 2026 YTD | $7.18 | $13.9 | +94% |
OGN has the edge over HIMS on returns for 2026, with the stronger performance.